anonymous
Guest
anonymous
Guest
If the company hires on any consultants with half a brain for the new drugs, they will realize it cannot be the same sales force. This combination is like oil and vinegar. They simply don't mix. There are too many problems with the entire scenario to list, but why damage the sales of OFIRMEV by adding this terrible distraction? Very bad idea.